NOVEL PI3K DELTA INHIBITORS AND METHODS OF USE THEREOF

• US 20100029693A1
• Filed: 08/10/2009
• Published: 02/04/2010
• Est. Priority Date: 08/14/2003
• Status: Abandoned Application

• Current Assignee: ICOS Corporation (Eli Lilly and Company)
• Original Assignee: ICOS Corporation (Eli Lilly and Company)
• Inventors: DOUANGPANYA, Jason, Puri, Kamal D., Hayflick, Joel S.
• Application Number:
  US12/538,748
• Publication Number:
  US 20100029693A1
• Time in Patent Office: Days
• US Class Current: 514/263.210
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to specific, selective, improved PI3Kδ inhibitors and methods of inhibiting undesirable levels of PI3Kδ activity using these PI3Kδ inhibitors to treat disorders mediated by PI3Kδ.

Claims

1. A compound having formula (III)

wherein R⁹, R¹⁰, R¹¹, and R¹², independently, are selected from the group consisting of hydrogen, C_1-6alkyl, or halo;

and

R¹³ is selected from the group consisting of C_1-6alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound is the S-enantiomer.

3. A pharmaceutical composition comprising an effective amount of a compound according to claim 1;

and at least one pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 and at least one pharmaceutically acceptable excipient.

5. A method of treating a condition in an individual in need thereof, comprising administering to the individual a compound according to claim 1, wherein the condition is selected from the group consisting of asthma, allergic rhinitis, multiple sclerosis, diabetes, chronic obstructive pulmonary disease, cancer, and lymphoma.

6. A method of treating a condition in an individual in need thereof, comprising administering to the individual a compound according to claim 2, wherein the condition is selected from the group consisting of asthma, allergic rhinitis, multiple sclerosis, diabetes, chronic obstructive pulmonary disease, cancer, and lymphoma.

7. A method of treating a condition in an individual in need thereof, comprising administering to the individual a compound according to claim 3, wherein the condition is selected from the group consisting of asthma, allergic rhinitis, multiple sclerosis, diabetes, chronic obstructive pulmonary disease, cancer, and lymphoma.

8. A method of treating a condition in an individual in need thereof, comprising administering to the individual a compound according to claim 4, wherein the condition is selected from the group consisting of asthma, allergic rhinitis, multiple sclerosis, diabetes, chronic obstructive pulmonary disease, cancer, and lymphoma.